CN1105799A - 作为基质金属蛋白酶抑制剂的喹诺酮衍生物 - Google Patents

作为基质金属蛋白酶抑制剂的喹诺酮衍生物 Download PDF

Info

Publication number
CN1105799A
CN1105799A CN94190137A CN94190137A CN1105799A CN 1105799 A CN1105799 A CN 1105799A CN 94190137 A CN94190137 A CN 94190137A CN 94190137 A CN94190137 A CN 94190137A CN 1105799 A CN1105799 A CN 1105799A
Authority
CN
China
Prior art keywords
amino
group
quinolone
compound
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94190137A
Other languages
English (en)
Chinese (zh)
Inventor
坂元城
今冈武
本山晶章
山本荣仁
高须英树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN1105799A publication Critical patent/CN1105799A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN94190137A 1993-03-18 1994-03-17 作为基质金属蛋白酶抑制剂的喹诺酮衍生物 Pending CN1105799A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP58264/93 1993-03-18
JP5826493 1993-03-18
JP256873/93 1993-10-14
JP25687393 1993-10-14

Publications (1)

Publication Number Publication Date
CN1105799A true CN1105799A (zh) 1995-07-26

Family

ID=26399315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94190137A Pending CN1105799A (zh) 1993-03-18 1994-03-17 作为基质金属蛋白酶抑制剂的喹诺酮衍生物

Country Status (7)

Country Link
EP (1) EP0641323A1 (enExample)
KR (1) KR950704257A (enExample)
CN (1) CN1105799A (enExample)
AU (1) AU672888B2 (enExample)
CA (1) CA2136108A1 (enExample)
TW (1) TW290541B (enExample)
WO (1) WO1994021612A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1113648C (zh) * 1996-04-04 2003-07-09 弗·哈夫曼-拉罗切有限公司 四氢－β－咔啉衍生物作为抗转移瘤剂的用途
CN108285469A (zh) * 2018-03-15 2018-07-17 遵义医学院 一种抗菌类喹诺酮衍生物及其制备方法和应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
WO1997019053A1 (en) 1995-11-23 1997-05-29 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
AU1529897A (en) * 1996-01-02 1997-07-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
JP4238334B2 (ja) 1996-09-10 2009-03-18 ヴァーナリス （アールアンドディー） リミテッド 細胞増殖抑制性ヒドロキサム酸誘導体
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
DE60219630T2 (de) 2001-06-15 2007-12-27 Vicuron Pharmaceuticals, Inc., Fremont Bicyclische pyrrolidinverbindungen
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP4394686B2 (ja) 2003-07-30 2010-01-06 大塚製薬株式会社 唾液分泌促進用医薬組成物およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1113648C (zh) * 1996-04-04 2003-07-09 弗·哈夫曼-拉罗切有限公司 四氢－β－咔啉衍生物作为抗转移瘤剂的用途
CN108285469A (zh) * 2018-03-15 2018-07-17 遵义医学院 一种抗菌类喹诺酮衍生物及其制备方法和应用
CN108285469B (zh) * 2018-03-15 2020-07-24 遵义医学院 一种抗菌类喹诺酮衍生物及其制备方法和应用

Also Published As

Publication number Publication date
EP0641323A1 (en) 1995-03-08
AU672888B2 (en) 1996-10-17
TW290541B (enExample) 1996-11-11
AU6263794A (en) 1994-10-11
CA2136108A1 (en) 1994-09-29
KR950704257A (ko) 1995-11-17
WO1994021612A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
CN1105799A (zh) 作为基质金属蛋白酶抑制剂的喹诺酮衍生物
CN1054380C (zh) 稠环化合物及其用途
CN1034869C (zh) 肽类化合物及其可药用盐的制备方法
CN1104419C (zh) 苯并吖庚因衍生物
CN1030251C (zh) 取代的4-(喹啉-2-基-甲氧基)苯乙酸衍生物的制备方法
CN1032203C (zh) 制备取代2-吡啶酮和吡啶-2-硫酮的方法
CN1489583A (zh) 新的生理活性物质
CN1121068A (zh) 脯氨酰胺衍生物
CN1063430C (zh) 乙醇胺衍生物
CN1198804C (zh) 酰胺化合物及其用途
CN1551881A (zh) 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
CN1618789A (zh) 可有效对抗c型肝炎病毒的巨环肽
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN1040211C (zh) 基质金属蛋白酶抑制剂
CN1265096A (zh) 肼衍生物
CN1329614A (zh) 稠合的哒嗪衍生物、它们的制备方法和用途
CN1816551A (zh) 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
CN1124734A (zh) 噻嗪-或硫氮杂䓬衍生物
CN1308071A (zh) 新的双环dna促旋酶抑制剂
CN1764648A (zh) 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
CN1956982A (zh) 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
CN1219932A (zh) 用作选择性凝血酶抑制剂的芳族脒衍生物
CN1054071A (zh) 口服的活性肾素抑制剂
CN1218467A (zh) 新的含酰胺键的硫衍生物,它们的制备方法,它们作为药物的用途以及含有它们的药物组合物
CN1140175A (zh) 7-酰基-3-(取代的氨基甲酰氧基)头孢烯化合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication